3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms, Male
1
Interventions
cabozantinib
5
Nivolumab
4
Ipilimumab
4
Axitinib
4
pembrolizumab
3
Blood Specimen Collection
3
zimberelimab
2
atezolizumab
2
Surveys and Questionnaires
2
Sunitinib
2
Irinotecan
2
temsirolimus
1
spartalizumab
1
salicylhydroxamic acid
1
palbociclib
1
orellanine
1
olaparib
1
liposomal doxorubicin
1
lenvatinib
1
gallium Ga 68 dotatate
1
fludarabine
1
brodalumab
1
belzutifan
1
aldesleukin
1
adagrasib
1
Vincristine
1
Temozolomide
1
Taxes
1
Selenomethionine
1
Ropivacaine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Genetic Counseling
×
90 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled